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Abstract
Introduction:	The	risk	of	pulmonary	thromboembolism	(PTE)	in	patients	with	exacerbated	chronic	obstructive	pulmonary	disease	
(e-COPD)	is	higher	than	in	non-COPD	states.	The	study	aimed	to	evaluate	the	prevalence	and	the	parameters	that	are	critical	for	
finding	the	incidence	of	PTE	in	patients	with	e-COPD.
Material and methods:	This	cross-sectional	study	was	performed	on	68	consecutive	patients	with	the	e-COPD,	referred	to	the	
Pulmonary	Disease	Department	at	the	Shariati	Hospital	in	Tehran	between	2013	and	2014.	In	addition	to	collecting	data	on	the	
history	of	disease	and	physical	examination,	arterial	blood	sampling,	spirometry,	electrocardiography	and	echocardiography	were	
performed	for	all	patients.	All	subjects	underwent	computed	tomography	pulmonary	angiography	(CT-PA)	as	a method	of	choice	
for	diagnosing	PTE.
Results:	Out	of	68	cases,	five	(7.4%)	had	CT	angiography	findings	suggesting	PTE.	These	patients	were	all	male	and	had	a higher	
mean	age	(79	vs.	65	years),	lower	mean	systolic	blood	pressure	(88.36	vs.	118.33	mmHg),	and	a higher	mean	heart	rate	(133.12	
vs	90.33	beats/min),	compared	to	e-COPD	patients	without	PTE.	Arterial	blood	gas	analysis	in	individuals	with	PTE	demonstrated	
a lower	HCO3	(2.33	vs.	9.44	mEq/l)	and	PCO2	(44.35	vs.	51.43	mm	Hg)	levels.	The	mean	left	ventricular	ejection	fraction	(LVEF)	
was	lower	in	patients	with	PTE	(34.14	±	4.49%	vs.	46.94	±	8.27%).
Conclusion:	The	prevalence	of	PTE	in	our	series	of	patients	with	e-COPD	was	7.4%.	According	to	the	study	results,	male	gender,	
advanced	age,	hypotension,	tachycardia,	and	respiratory	alkalosis	are	factors	indicating	possible	PTE	among	subjects	with	e-
COPD.
Key words:	pulmonary	thromboembolism	(PTE),	exacerbated	COPD	(e-COPD),	computed	tomography	pulmonary	angiography	
(CT-PA),	systolic	blood	pressure	(SBP),	left	ventricular	ejection	fraction	(LVEF)
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Introduction
Diagnosis and management of exacerbated 
chronic obstructive pulmonary disease (e-COPD) 
are challenging in both ambulatory and inpatient 
clinical settings [1]. In addition, e-COPD can ac-
company and mask the features of a number of car-
diopulmonary conditions, including PTE, which 
makes the situation even more complicated [2]. 
In fact, because of their frequent concomitant 
occurrence, there are no proven clinical criteria 
to help delineate PTE from COPD [3]. This is at-
tributable to the overlapping clinical features and 
the non-specificity of the signs and symptoms of 
both conditions [4]. Both of the disorders can have 
an insidious onset. Unlike e-COPD, which is re-
cognized clinically, imaging studies are required 
to confirm the diagnosis of PTE [5].
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Given the high mortality rates among pa-
tients with untreated PTE reaching 25% in some 
individuals, it is crucial to consider PTE when 
managing patients with e-COPD [6].
The risk of PTE in COPD patients is twice 
that of non-COPD states [7, 8]. PTE is expected 
to develop in almost one-fifth of subjects with 
COPD and the simultaneous occurrence of these 
conditions can lead to a significant increase in 
morbidity and mortality rates [9, 10]. Optimal 
management of these patients requires timely 
diagnosis, and this, in turn, necessitates a high 
index of clinical suspicion. 
This study was designed to highlight clini-
cal and paraclinical parameters that can predict 
a high risk of concomitant PTE in patients with 
e-COPD.
Material and methods
Study design and population
This is a cross-sectional study, performed at 
the Department of Pulmonary Diseases, Shariati 
Hospital affiliated to Tehran University of Medical 
Sciences in 2013 and 2014. Sixty-eight consecu-
tive patients with e-COPD were enrolled. 
Inclusion criteria
Patients who were diagnosed with COPD 
basing on their signs and symptoms, medical and 
family history and results of pulmonary function 
tests (spirometry). The consensus over the defi-
nition of e-COPD, achieved by a working group 
in 2000, was used to identify the study subjects: 
a sustained worsening of a patient’s condition, 
from a stable state and beyond normal daily-varia-
tions, which is acute in the onset and necessitates 
a change in the regular medication in a patient 
with underlying COPD [11, 12]. 
Exclusion criteria
Individuals with a history of warfarin use, ac-
tive cancer, surgery within the last two months, or 
not allowed to use contrast media, were excluded. 
Methods
After admission, a complete history — taking 
and a physical examination were performed. An 
arterial blood sample was obtained to assess blo-
od gases. Furthermore, an electrocardiogram test 
was carried out to detect abnormalities in heart 
rate, blocks, atrial fibrillation, ST-T changes, or 
the presence of the SlQ3T3 pattern. Echocardio-
graphy was also performed to show evidence of 
pulmonary PTE, including right ventricular hy-
pokinesia or intraventricular septum deviation. 
Patients also did a  pulmonary function test. 
Finally, within three days of their admission, 
all subjects underwent computed tomography 
pulmonary angiography (CTPA) to detect PTE, 
as this is the method of choice for diagnosing 
PTE in our center. For patients with a BMI <30, 
130 ml of contrast media, the administered 
slice thickness was 3 mm, and the voltage was 
120 sq. For individuals with a BMI above 30, 
150 ml of contrast media, a slice thickness of 
2 mm and a voltage of 140 kv were selected. 
Thromboembolism was defined as intraluminal 
filling defects or obstruction of the pulmonary 
vessel lumen.
Statistical analysis
Quantitative variables were presented as the 
mean ± standard deviation (SD) and were sum-
marized by absolute frequencies and percentages 
for categorical variables. Categorical variables 
were compared using chi-square test or Fisher 
exact test when more than 20% of cells with an 
expected count of less than 5 were observed. 
Quantitative variables were also compared with 
t-test or Mann-Whitney U test. For the statistical 
analysis, SPSS version 16.0 (SPSS Inc., Chicago, 
IL) was employed. P values  of 0.05 or less were 
considered statistically significant.
Results
A total of 68 subjects (38 males, 55.9%) with 
e-COPD entered the study. Patients had a mean 
age of 67.75 ± 9.26 years (range 50 to 88 years 
and a median 68 years). Five cases (7.4%) showed 
positive CT angiography findings for PTE. A com-
parison of the different clinical and paraclinical 
characteristics of e-COPD patients with and 
without PTE is presented in Table 1.
Patients with PTE showed significantly lower 
systolic blood pressure (SBP), arterial blood CO2 
pressure, arterial blood HC03 concentration and 
left ventricular ejection fraction (LVEF) compared 
with those without PTE. Parameters, including the 
patient’s age and mean heart rate were significan-
tly higher in subjects with PTE compared with 
the other group. Although individuals with PTE 
had statistically significant higher arterial blood 
pH, the difference is not clinically significant. The 
two groups were statistically different in terms of 
diastolic blood pressure, arterial O2 saturations 
before or after receiving nasal oxygen, FEV1, FVC, 
pulmonary artery pressure (PAP), or mitral valve 
regurgitation.
Advances in Respiratory Medicine 2018, vol. 86, no. 4, pages 168–171 
170 www.journals.viamedica.pl
Discussion
Our study was designed to assess the preva-
lence of PTE among patients with COPD and 
to determine the clinical and paraclinical pa-
rameters that could suggest a  higher risk of 
PTE in patients with e-COPD. According to the 
study results, gender and advanced age seem 
to be factors potentially affecting the incidence 
of PTE. Patients with PTE were male and had 
a higher mean age in comparison with the gro-
up without detectable thromboembolism. Our 
results contrasted those of Chen et al. [12] who 
found a lower average age among their series of 
patients with PTE.
Other findings include lower SBP, higher re-
spiratory rate and increased heart rate in PTE sub-
jects, all of which are expected discoveries in this 
setting. In a survey conducted by Stein et al. [13], 
tachypnea was found in 73%, tachycardia in 30%, 
and pleuritic chest pain in 66% of patients with 
PTE. Tachycardia was a more permanent and va-
lid feature of PTE in other studies, and heart rate 
less than 90 beats/min contradicted the diagnosis 
[14]. The studies of arterial blood gasses could 
also help raise suspicion for PTE. Patients with 
COPD exacerbation usually develop hypercapnia 
due to ventilation failure, the severity of which 
correlates with the severity of the exacerbation. 
In addition, a rise in HCO3 is expected in these 
patients. In contrast, individuals with PTE lose 
more blood CO2 due to their tachypnea state, and 
the levels of HCO3 drop as well as produce a state 
of respiratory alkalosis. Therefore, a low or nor-
mal pCO2 level, as well as reduced HCO3 levels 
during COPD exacerbation, could be indicative 
of a simultaneous PTE.
Patients with COPD develop pulmonary hy-
pertension as their earliest cardiovascular com-
plication. Endothelial dysfunction, destruction 
and altered tonicity of the pulmonary vascular 
bed as well as changes in blood gas exchange are 
the respiratory mechanisms. However, the cardiac 
compensatory mechanisms manage to maintain 
normal cardiac output in the stable state. Therefo-
re, left-sided heart failure is not a common finding 
in patients with COPD. A review of the prevalence 
of left ventricular systolic dysfunction in subjects 
with COPD showed a prevalence of 10–40% in 
unselected COPD patients and a prevalence of 
23–32% in individuals with an exacerbation of 
the disease. However, left ventricular systolic 
dysfunction was not a common finding among 
selected COPD patients in whom coronary artery 
disease was excluded (0–16%) [15]. Therefore, 
while a reduction in LVEF is expected in a number 
of patients with e-COPD, this reduction should 
raise suspicion of superimposed PTE, since low 
Table 1. Comparison of the patients with and without pulmonary thromboembolism (PTE)
Characteristics PTE (n = 5) Non-PTE (n = 63) p-values
Age,	year,	mean	(range),	median 65.7	(64–81)
63
66.9	(63–83)
61
0.35
Male/female,	number	(%) 3	(60)/2	(40) 30	(47.6)/33	(52.4) 0.103*
Systolic	blood	pressure,	mm	Hg,	Mean	(±	SD) 88.3	(±	1.53) 118.3	(±	20.18) <	0.001
Diastolic	blood	pressure,	mm	Hg,	Mean	(±	SD) 65.0	(±	5.0) 73.90	(±	13.11) 0.064
Heart	rate,	Mean	(±	SD) 132.0	(±	7.21) 90.33	(±	12.07) <	0.001
Arterial	blood	saturation,	Mean	(±	SD) 93.33	(±	7.64) 85.00	(±	10.44) 0.101
Arterial	blood	gas
PH,	Mean	(±	SD)
Co2,	Mean	(±	SD)
HCO3,	Mean	(±	SD)
7.46	(±	0.03)
42.33	(±	2.52)
2.3	(±	0.00)
7.36	(±	0.06)
51.43	(±	11.91)
3.25	(±	9.44)
0.024
0.002
<	0.01
Spirometry
FVC,	Mean	(±	SD)
FEV1,	Mean	(±	SD)
58.81	(±	12.00)
4.41	(±	12.00)
60.59	(±	15.93)
5.15	(±	19.98)
0.559
0.779
Cardiovascular
LVEF,	Mean	(±	SD)
PAP,	Mean	(±	SD)
35.00	(±	5.00)
36.00	(±	1.00)
46.94	(±	8.27)
42.35	(±	16.26)
0.038
0.505
Heart	valve	abnormalities
MR
Tricuspid
0	(0.0%)
1	(20%)
12	(19.0%)
12	(19.0%)
0.039
0.705
*	Comparison	has	been	made	 inside	each	group;	FVC:	 forced	vital	 capacity;	 FEV1:	 forced	expiratory	volume	 in	1	 second;	 LVEF:	 left	 ventricular	 ejection	 fraction;	
MR:	mitral	regurgitation;	PAP:	pulmonary	artery	pressure	
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LVEF is not a constant feature in subjects with 
e-COPD.
In this study, the prevalence of PTE among 
e-COPD patients was 7.4%, which is considerably 
lower than that reported in other surveys (Range 
3.3–33%) [16–20]. It is possible that a number 
of persons with both PTE and e-COPD, who had 
a more critical condition, were primarily diagno-
sed with PTE, or had expired in the emergency 
department, therefore did not enter the study. In 
addition, the failure of CT-PA to diagnose a smal-
ler peripheral embolism might have contributed 
to the obtained low figure.
Conclusion
The prevalence of PTE in patients with e-
COPD is higher than that expected in the general 
population or non-COPD conditions. Therefore, 
physicians attending these patients need to keep 
this correlation in mind for their timely diagnosis 
and management. However, it is usually not easy 
to diagnose PTE in the context of e-COPD because 
of their numerous common clinical features and 
PTE symptoms and non-specificity. The results of 
our study suggest that in patients with e-COPD, 
a number of parameters could raise the possibility 
of concurrent PTE. According to these results, 
a drop in systolic blood pressure, tachycardia, the 
normocapneic state with decreased HCO3 levels 
and a significant decrease in LVEF are findings in 
e-COPD patients which should warn the physi-
cian of a possible concomitant PTE.
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